
Twice-daily dosing of the oral JAK inhibitor deuruxolitinib nearly tripled response rates over once-daily dosing in severe alopecia areata.
The American Journal of Managed Care
almost 23 years ago
The Ripple Effects of a Restrictive Medicaid Formularyalmost 23 years ago
A Clinical Decision and Economic Analysis Model of Cancer Pain Management





